FDA recall D-1075-2014

Teva Pharmaceuticals USA · Class II · drug

Product

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

Reason for recall

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Distribution

Nationwide

Key facts

Status
Terminated
Initiation date
2013-12-18
Report date
2014-02-12
Termination date
2014-10-22
Voluntary/Mandated
Voluntary: Firm initiated
Location
Horsham, PA, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1075-2014